On the use of Markov models in pharmacoeconomics: pros and cons and implications for policy makers

A Carta, C Conversano - Frontiers in public health, 2020 - frontiersin.org
We present an overview of the main methodological features and the goals of
pharmacoeconomic models that are classified in three major categories: regression models …

How much are we willing to pay to prevent a fall? Cost-effectiveness of a multifactorial falls prevention program for community-dwelling older adults

KB Jenkyn, JS Hoch, M Speechley - Canadian Journal on Aging/La …, 2012 - cambridge.org
This study examined the cost-effectiveness of a multifactorial falls prevention program and
estimated the trade-off between the extra costs of such a program and the additional …

Who benefits most from collaborative dementia care from a patient and payer perspective? A subgroup cost-effectiveness analysis

A Rädke, B Michalowsky, JR Thyrian… - Journal of …, 2020 - content.iospress.com
Background: Dementia care management (DCM) aims to provide optimal treatment for
people with dementia (PwD). Treatment and care needs are dependent on patients' …

The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review

M Sonntag, HH Koenig, A Konnopka - Pharmacoeconomics, 2013 - Springer
Objective To systematically review approaches and instruments used to derive utility weights
in cost-utility analyses (CUAs) within the field of mental disorders and to identify factors that …

A review and critique of studies reporting utility values for schizophrenia-related health states

I Mavranezouli - Pharmacoeconomics, 2010 - Springer
Economic evaluation of health technologies in the form of cost-utility analysis is increasingly
advocated. The most common outcome measure in this type of analysis is the QALY. In …

Estudio de costo-efectividad del tratamiento de la esquizofrenia en México

MC Lara-Muñoz, R Robles-García, R Orozco… - Salud mental, 2010 - scielo.org.mx
SM 10.03.01 - Estudio costo-efectividad esquizofrenia.pmd Page 1 Costo-efectividad del
tratamiento de la esquizofrenia en México 211 Vol. 33, No. 3, mayo-junio 2010 Artículo original …

Cost-effectiveness analysis of olanzapine and risperidone in schizophrenic patients in the Indian healthcare settings of Andhra Pradesh, India

Y Praveena, KH Sandhya, GM Ram… - Journal of …, 2020 - academic.oup.com
Objectives The prevalence of schizophrenia in Andhra Pradesh, India is 279, and the crude
disability-adjusted life year is 177 per 100 thousand people. It is one of the major mental …

Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia

H Quitian Reyes, JA Arciniegas Barrera… - Revista Colombiana …, 2016 - scielo.org.co
Abstract QUITIAN REYES, Hoover; ARCINIEGAS BARRERA, Jair Alberto; BOHORQUEZ
PENARANDA, Adriana and GOMEZ RESTREPO, Carlos. Cost-effectiveness of …

Systematic literature review of the methods used to compare newer second-generation agents for the management of schizophrenia: A focus on health technology …

G Kruse, BJO Wong, MS Duh, P Lefebvre… - …, 2015 - Springer
Background The challenges of comparative effectiveness to support health technology
assessment (HTA) agencies are important considerations in the choices of antipsychotic …

Cost-effectiveness of atypical antipsychotics for the treatment of schizophrenia

A Santos, CE Vidal, C Brandão - Jornal Brasileiro de Economia da …, 2016 - jbes.com.br
Objectives: To conduct a cost-effectiveness analysis of second-generation antipsychotics
(SGA) for schizophrenia in Brazil. Methods: A Markov model was built for the evaluation of …